Cargando…

Oncolytic Virus-Mediated RAS Targeting in Rhabdomyosarcoma

Aberrant activation of the receptor tyrosine kinase-mediated RAS signaling cascade is the primary driver of embryonal rhabdomyosarcoma (ERMS), a pediatric cancer characterized by a block in myogenic differentiation. To investigate the cellular function of activated RAS signaling in regulating the gr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Phelps, Michael P., Yang, Heechang, Patel, Shivani, Rahman, Masmudur M., McFadden, Grant, Chen, Eleanor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197336/ https://www.ncbi.nlm.nih.gov/pubmed/30364635 http://dx.doi.org/10.1016/j.omto.2018.09.001

Ejemplares similares

Oncolytic Virotherapy with Myxoma Virus
por: Rahman, Masmudur M., et al.
Publicado: (2020)

Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
por: Rahman, Masmudur M., et al.
Publicado: (2021)

Oncolytic Virotherapy for Hematological Malignancies
por: Bais, Swarna, et al.
Publicado: (2012)

Identification of host DEAD-box RNA helicases that regulate cellular tropism of oncolytic Myxoma virus in human cancer cells
por: Rahman, Masmudur M., et al.
Publicado: (2017)

NSCs are permissive to oncolytic Myxoma virus and provide a delivery method for targeted ovarian cancer therapy
por: Cornejo, Yvonne, et al.
Publicado: (2020)

Myxoma Virus-Encoded Host Range Protein M029: A Multifunctional Antagonist Targeting Multiple Host Antiviral and Innate Immune Pathways
por: Rahman, Masmudur M., et al.
Publicado: (2020)

The Oncolytic Activity of Myxoma Virus against Soft Tissue Sarcoma Is Mediated by the Overexpression of Ribonucleotide Reductase
por: Woo, Yanghee, et al.
Publicado: (2021)

Simultaneous Tumor and Stroma Targeting by Oncolytic Viruses
por: Everts, Anne, et al.
Publicado: (2020)

Myxoma Virus dsRNA Binding Protein M029 Inhibits the Type I IFN-Induced Antiviral State in a Highly Species-Specific Fashion
por: Rahman, Masmudur M., et al.
Publicado: (2017)

RNA Helicase A/DHX9 Forms Unique Cytoplasmic Antiviral Granules That Restrict Oncolytic Myxoma Virus Replication in Human Cancer Cells
por: Rahman, Masmudur M., et al.
Publicado: (2021)

Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma
por: Jazowiecka-Rakus, Joanna, et al.
Publicado: (2020)

Modulation of Tumor Necrosis Factor by Microbial Pathogens
por: Rahman, Masmudur M, et al.
Publicado: (2006)

Modulation of NF-κB signalling by microbial pathogens
por: Rahman, Masmudur M., et al.
Publicado: (2011)

Role of cytokines in poxvirus host tropism and adaptation
por: Rahman, Masmudur M, et al.
Publicado: (2022)

Oncolytic Viruses and the Immune System: The Dynamic Duo
por: Lemos de Matos, Ana, et al.
Publicado: (2020)

Co-Regulation of NF-κB and Inflammasome-Mediated Inflammatory Responses by Myxoma Virus Pyrin Domain-Containing Protein M013
por: Rahman, Masmudur M., et al.
Publicado: (2009)

Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
por: Rahman, Masmudur M., et al.
Publicado: (2023)

Tumor Tropism of DNA Viruses for Oncolytic Virotherapy
por: Enow, Junior A., et al.
Publicado: (2023)

Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor
por: Lilly, Cameron L., et al.
Publicado: (2016)

Myxoma Virus Protein M029 Is a Dual Function Immunomodulator that Inhibits PKR and Also Conscripts RHA/DHX9 to Promote Expanded Host Tropism and Viral Replication
por: Rahman, Masmudur M., et al.
Publicado: (2013)

Advances in oncolytic virotherapy
por: Russell, Stephen J., et al.
Publicado: (2022)

Cytokine determinants of viral tropism
por: McFadden, Grant, et al.
Publicado: (2009)

Autologous Transplantation Using Donor Leukocytes Loaded Ex Vivo with Oncolytic Myxoma Virus Can Eliminate Residual Multiple Myeloma
por: Villa, Nancy.Y., et al.
Publicado: (2020)

Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies
por: Villa, Nancy Y., et al.
Publicado: (2016)

Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma
por: Villa, Nancy Y., et al.
Publicado: (2022)

Combination of LIGHT (TNFSF14)-Armed Myxoma Virus Pre-Loaded into ADSCs and Gemcitabine in the Treatment of Experimental Orthotopic Murine Pancreatic Adenocarcinoma
por: Jazowiecka-Rakus, Joanna, et al.
Publicado: (2022)

Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo
por: Weng, Mingzhe, et al.
Publicado: (2014)

Myxoma Virus Targets Primary Human Leukemic Stem and Progenitor Cells While Sparing Normal Hematopoietic Stem and Progenitor Cells
por: Kim, Manbok, et al.
Publicado: (2009)

A cautionary note on the selectivity of oncolytic poxviruses
por: Tang, Bingtao, et al.
Publicado: (2019)

RIG-I Mediates the Co-Induction of Tumor Necrosis Factor and Type I Interferon Elicited by Myxoma Virus in Primary Human Macrophages
por: Wang, Fuan, et al.
Publicado: (2008)

Convergent Loss of the Necroptosis Pathway in Disparate Mammalian Lineages Shapes Viruses Countermeasures
por: Águeda-Pinto, Ana, et al.
Publicado: (2021)

Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma()
por: Waters, Alicia M., et al.
Publicado: (2016)

Analysis of Vaccinia Virus−Host Protein−Protein Interactions: Validations of Yeast Two-Hybrid Screenings
por: Zhang, Leiliang, et al.
Publicado: (2009)

Myxoma Virus Expressing LIGHT (TNFSF14) Pre-Loaded into Adipose-Derived Mesenchymal Stem Cells Is Effective Treatment for Murine Pancreatic Adenocarcinoma
por: Jazowiecka-Rakus, Joanna, et al.
Publicado: (2021)

Role of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma
por: Slemmons, Katherine K., et al.
Publicado: (2015)

Resistance to Oncolytic Myxoma Virus Therapy in Nf1(−/−)/Trp53(−/−) Syngeneic Mouse Glioma Models Is Independent of Anti-Viral Type-I Interferon
por: Zemp, Franz J., et al.
Publicado: (2013)

Systemic Delivery of mLIGHT-Armed Myxoma Virus Is Therapeutic for Later-Stage Syngeneic Murine Lung Metastatic Osteosarcoma
por: Christie, John D., et al.
Publicado: (2022)

TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma
por: Hutzen, Brian, et al.
Publicado: (2017)

Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models
por: Chen, Chun-Yu, et al.
Publicado: (2017)

Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model
por: Dobson, Christine C, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_48vm422mq7r0aqn65k1hupkcd4